PL2178881T3 - Nowe pochodne 6-triazolopirydazynosulfanylobenzotiazolu i benzimidazolu, sposób ich wytwarzania, ich zastosowanie jako leków, kompozycje farmaceutyczne i nowe zastosowanie zwłaszcza jako inhibitorów MET - Google Patents

Nowe pochodne 6-triazolopirydazynosulfanylobenzotiazolu i benzimidazolu, sposób ich wytwarzania, ich zastosowanie jako leków, kompozycje farmaceutyczne i nowe zastosowanie zwłaszcza jako inhibitorów MET

Info

Publication number
PL2178881T3
PL2178881T3 PL08845285T PL08845285T PL2178881T3 PL 2178881 T3 PL2178881 T3 PL 2178881T3 PL 08845285 T PL08845285 T PL 08845285T PL 08845285 T PL08845285 T PL 08845285T PL 2178881 T3 PL2178881 T3 PL 2178881T3
Authority
PL
Poland
Prior art keywords
novel
triazolopyridazinesulfanyl
benzothiazole
medicaments
production
Prior art date
Application number
PL08845285T
Other languages
English (en)
Polish (pl)
Inventor
Eva Albert
Eric Bacque
Conception Nemecek
Antonio Ugolini
Sylvie Wentzler
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40524792&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2178881(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from FR0705789A external-priority patent/FR2919870B1/fr
Priority claimed from FR0801819A external-priority patent/FR2929613B1/fr
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of PL2178881T3 publication Critical patent/PL2178881T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/82—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
PL08845285T 2007-08-09 2008-08-06 Nowe pochodne 6-triazolopirydazynosulfanylobenzotiazolu i benzimidazolu, sposób ich wytwarzania, ich zastosowanie jako leków, kompozycje farmaceutyczne i nowe zastosowanie zwłaszcza jako inhibitorów MET PL2178881T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
FR0705789A FR2919870B1 (fr) 2007-08-09 2007-08-09 Nouveaux derives de 6-triazolopyridazine-sulfanyl benzothiazole et benzothiazole et benzimidazole, procede, compositions pharmaceutiques et nouvelle utilisation comme inhibiteurs de cmet
FR0801819A FR2929613B1 (fr) 2008-04-02 2008-04-02 Nouveaux derives de 6-triazolopyridazine-sulfanyl benzothiazole et benzimidazole,leur preparation,comme medicaments et utilisation notamment comme inhibiteurs de met
EP08845285.9A EP2178881B1 (fr) 2007-08-09 2008-08-06 Nouveaux derives de 6-triazolopyridazine-sulfanyl benzothiazole et benzimidazole, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteurs de met
PCT/FR2008/001172 WO2009056692A2 (fr) 2007-08-09 2008-08-06 Nouveaux derives de 6-triazolopyridazine-sulfanyl benzothiazole et benzimidazole, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteurs de met

Publications (1)

Publication Number Publication Date
PL2178881T3 true PL2178881T3 (pl) 2014-03-31

Family

ID=40524792

Family Applications (1)

Application Number Title Priority Date Filing Date
PL08845285T PL2178881T3 (pl) 2007-08-09 2008-08-06 Nowe pochodne 6-triazolopirydazynosulfanylobenzotiazolu i benzimidazolu, sposób ich wytwarzania, ich zastosowanie jako leków, kompozycje farmaceutyczne i nowe zastosowanie zwłaszcza jako inhibitorów MET

Country Status (41)

Country Link
US (3) US8546393B2 (fr)
EP (1) EP2178881B1 (fr)
JP (1) JP5694767B2 (fr)
KR (1) KR101654376B1 (fr)
CN (1) CN101801973B (fr)
AR (1) AR068055A1 (fr)
AU (1) AU2008320791B2 (fr)
BR (1) BRPI0815606A2 (fr)
CA (2) CA2884102A1 (fr)
CL (1) CL2008002351A1 (fr)
CO (1) CO6251270A2 (fr)
CR (1) CR11252A (fr)
CY (1) CY1114906T1 (fr)
DK (1) DK2178881T3 (fr)
DO (1) DOP2010000040A (fr)
EA (1) EA023465B1 (fr)
EC (1) ECSP109944A (fr)
ES (1) ES2436657T3 (fr)
GT (1) GT201000023A (fr)
HR (1) HRP20131182T1 (fr)
IL (1) IL203734A (fr)
JO (1) JO2935B1 (fr)
MA (1) MA31685B1 (fr)
ME (1) ME00972B (fr)
MX (2) MX2010001593A (fr)
MY (1) MY152535A (fr)
NI (1) NI201000022A (fr)
NZ (1) NZ583177A (fr)
PA (1) PA8792501A1 (fr)
PE (1) PE20090900A1 (fr)
PL (1) PL2178881T3 (fr)
PT (1) PT2178881E (fr)
RS (1) RS53078B (fr)
SG (1) SG183077A1 (fr)
SI (1) SI2178881T1 (fr)
TN (1) TN2010000026A1 (fr)
TW (1) TWI429649B (fr)
UA (1) UA101328C2 (fr)
UY (1) UY31277A1 (fr)
WO (1) WO2009056692A2 (fr)
ZA (1) ZA201000912B (fr)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PA8792501A1 (es) 2007-08-09 2009-04-23 Sanofi Aventis Nuevos derivados de 6-triazolopiridacina-sulfanil benzotiazol y bencimidazol,su procedimiento de preparación,su aplicación como medicamentos,composiciones farmacéuticas y nueva utilización principalmente como inhibidores de met.
CN102159559A (zh) * 2008-07-18 2011-08-17 赛诺菲-安万特 新型咪唑并[1,2-a]吡啶衍生物、其制备方法、其作为药物的用途、其药物组合物和新型用途特别是作为MET抑制剂的新型用途
FR2941229B1 (fr) * 2009-01-21 2012-11-30 Sanofi Aventis Nouveaux derives triazolo°4,3-a!pyridine, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteurs de met
FR2945806B1 (fr) * 2009-05-19 2013-04-05 Sanofi Aventis Nouveaux derives imidazo[1,2-a]pyridine,procede de preparation,medicaments,compositions pharmaceutiques et utilisation notamment comme inhibiteurs de met
JP2011528337A (ja) * 2008-07-18 2011-11-17 サノフイ−アベンテイス 新規トリアゾロ［４，３−ａ］ピリジン誘導体、これらの調製方法、医薬としてのこれらの使用、医薬組成物および、特にｍｅｔ阻害剤としての、新規使用
UY32049A (es) 2008-08-14 2010-03-26 Takeda Pharmaceutical Inhibidores de cmet
FR2941949B1 (fr) * 2009-02-06 2011-04-01 Sanofi Aventis Derives de 6-(6-o-cycloalkyl ou 6-nh-cycloalkyl- triazolopyridazine-sulfanyl)benzothiazoles et benzimidazoles preparation, application comme medicaments et utilisation comme inhibiteurs de met.
FR2941950B1 (fr) * 2009-02-06 2011-04-01 Sanofi Aventis Derives de 6-(6-o-substitue-triazolopyridazine-sulfanyl) benzothiazoles et benzimidazoles : preparation, application comme medicaments et utilisation comme inhibiteurs de met.
FR2941952B1 (fr) * 2009-02-06 2011-04-01 Sanofi Aventis Derives de 6-(6-substitue-triazolopyridazine-sulfanyl) 5-fluoro-benzothiazoles et 5-fluoro-benzimidazoles : preparation, application comme medicaments et utilisation comme inhibiteurs de met.
FR2941951B1 (fr) * 2009-02-06 2011-04-01 Sanofi Aventis Derives de 6-(6-nh-substitue-triazolopyridazine-sulfanyl) benzothiazoles et benzimidazoles : preparation, application comme medicaments et utilisation comme inhibiteurs de met.
MX2011008452A (es) * 2009-02-10 2011-12-16 Astrazeneca Ab Derivados de triazolo [4,3-b] piridazina y sus usos para el cancer de prostata.
AU2010247190A1 (en) * 2009-05-11 2011-11-10 Astrazeneca Ab [1,2,4] triazolo [4,3-b] pyridazines as ligands of the androgen receptor
EA030141B1 (ru) 2009-12-31 2018-06-29 Хатчисон Медифарма Лимитед Определенные триазолопиридины и триазолопиразины, их композиции и способы их применения
TW201202242A (en) 2010-03-30 2012-01-16 Sanofi Aventis 6-(alkyl-or cycloalkyl-triazolopyridazine-sulfanyl)benzo-thiazole derivatives: preparation, and use as medicaments and as MET inhibitors
FR2958292A1 (fr) * 2010-03-30 2011-10-07 Sanofi Aventis Derives de 6-(alkyl- ou cycloalkyl-triazolopyridazine-sulfanyl) benzothiazoles: preparation, application comme medicaments et utilisation comme inhibiteurs de met
FR2966151B1 (fr) * 2010-10-14 2012-11-09 Sanofi Aventis Derives de 6-(alkyl- ou cycloalkyl-triazolopyridazine-sulfanyl) benzothiazoles: preparation, application comme medicaments et utilisation comme inhibiteurs de met
US20130315895A1 (en) 2010-07-01 2013-11-28 Takeda Pharmaceutical Company Limited COMBINATION OF A cMET INHIBITOR AND AN ANTIBODY TO HGF AND/OR cMET
AR085183A1 (es) 2010-07-30 2013-09-18 Lilly Co Eli Compuesto 6-(1-metil-1h-pirazol-4-il)-3-(2-metil-2h-indazol-5-iltio)-[1,2,4]triazol[4,3-b]piridazina, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para tratar cancer
UA117092C2 (uk) 2011-09-06 2018-06-25 Байєр Інтеллектуал Проперті Гмбх Амінозаміщені імідазопіридазини
CA2848809A1 (fr) 2011-09-15 2013-03-21 Novartis Ag 3-(quinolin-6-ylthio)-[1,2,4]triazolo[4,3-a]pyradines substituees en position 6 a activite tyrosine kinase
BR112015000497A2 (pt) * 2012-07-12 2017-06-27 Sanofi Sa composição anti-tumoral compreendendo o composto 1-(6-{[6-(4-fluorofenil)[1,2,4]triazolo[4,3-b]piridazin-3-il]sulfanil}-1,3-benzotiazol-2-il)-3-(2-morfolin-4-iletil)ureia
ES2646916T3 (es) 2012-11-19 2017-12-18 Bayer Pharma Aktiengesellschaft Aminoimidazopiridazinas como inhibidores de MKNK1 cinasa
TWI695837B (zh) 2014-12-04 2020-06-11 比利時商健生藥品公司 作為激酶調節劑之三唑並嗒
JP6864953B2 (ja) 2014-12-09 2021-04-28 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル Ａｘｌに対するヒトモノクローナル抗体
WO2016135041A1 (fr) 2015-02-26 2016-09-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Protéines de fusion et anticorps les contenant pour favoriser l'apoptose
US10047071B1 (en) 2018-01-15 2018-08-14 King Saud University Dihydropyrimidinone derivatives
CN110317216A (zh) * 2018-03-28 2019-10-11 首都医科大学 一种三唑并哒嗪类衍生物在医药领域的应用
EA202192575A1 (ru) 2019-03-21 2022-01-14 Онксео Соединения dbait в сочетании с ингибиторами киназ для лечения рака
CN110041311B (zh) * 2019-05-20 2021-03-19 东南大学 一种荧光探针分子ml-fp及其制备方法和应用
US12570637B2 (en) 2019-06-12 2026-03-10 Bristol-Myers Squibb Company Crystalline salt forms 6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)-n-(methyld3) pyridazine-3-carboxamide
CN114761006A (zh) 2019-11-08 2022-07-15 Inserm(法国国家健康医学研究院) 对激酶抑制剂产生耐药性的癌症的治疗方法
WO2021148581A1 (fr) 2020-01-22 2021-07-29 Onxeo Nouvelle molécule dbait et son utilisation
AU2024241633A1 (en) 2023-03-30 2025-11-06 Revolution Medicines, Inc. Compositions for inducing ras gtp hydrolysis and uses thereof
TW202508595A (zh) 2023-05-04 2025-03-01 美商銳新醫藥公司 用於ｒａｓ相關疾病或病症之組合療法
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
AU2024360465A1 (en) 2023-10-12 2026-04-09 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2025171296A1 (fr) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Inhibiteurs de ras
TW202547461A (zh) 2024-05-17 2025-12-16 美商銳新醫藥公司 Ｒａｓ抑制劑
WO2025255438A1 (fr) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Procédés de traitement d'une maladie ou d'un trouble lié à la protéine ras
WO2025265060A1 (fr) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Compositions thérapeutiques et procédés de gestion d'effets liés au traitement
WO2026006747A1 (fr) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Inhibiteurs de ras
WO2026015796A1 (fr) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Méthodes de traitement d'une maladie ou d'un trouble lié à ras
WO2026015801A1 (fr) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Méthodes de traitement d'une maladie ou d'un trouble liés à ras
WO2026015825A1 (fr) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Utilisation d'un inhibiteur de ras pour traiter le cancer du pancréas
WO2026015790A1 (fr) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Méthodes de traitement d'une maladie ou d'un trouble lié à ras
WO2026050446A1 (fr) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Inhibiteurs de ras
WO2026072904A2 (fr) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions et méthodes de traitement du cancer du poumon

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2499995A1 (fr) 1981-02-13 1982-08-20 Roussel Uclaf Nouvelles oximes derivees de l'acide 3-alkyloxy ou 3-alkylthiomethyl 7-amino thiazolylacetamido cephalosporanique, leur preparation, leur application comme medicaments, les compositions les renfermant et les nouveaux intermediaires obtenus.
CA2339275A1 (fr) * 1998-09-11 2000-03-23 Warner-Lambert Company Les 5,6-dihydro-4-hydroxy-2-pyranones en tant qu'inhibiteurs de la protease aspartyl du vih
EP1298125A1 (fr) 2001-09-26 2003-04-02 Aventis Pharma S.A. Benzimidazoles substitués et leur usage comme traitement du cancer
KR20080080584A (ko) * 2005-11-30 2008-09-04 버텍스 파마슈티칼스 인코포레이티드 ｃ-Ｍｅｔ의 억제제 및 이의 용도
HRP20170103T1 (hr) * 2005-12-21 2017-03-24 Janssen Pharmaceutica N.V. Triazolopiridazini kao modulatori tirozin kinaze
CA2651979A1 (fr) * 2006-05-30 2007-12-06 Pfizer Products Inc. Derives de la triazolopyridazine
PE20080403A1 (es) * 2006-07-14 2008-04-25 Amgen Inc Derivados heterociclicos fusionados y metodos de uso
BRPI0717320A2 (pt) * 2006-10-23 2013-10-22 Sgx Pharmaceuticals Inc Triazóis bicíclicos como moduladores de proteína cinase
PA8792501A1 (es) 2007-08-09 2009-04-23 Sanofi Aventis Nuevos derivados de 6-triazolopiridacina-sulfanil benzotiazol y bencimidazol,su procedimiento de preparación,su aplicación como medicamentos,composiciones farmacéuticas y nueva utilización principalmente como inhibidores de met.

Also Published As

Publication number Publication date
JP5694767B2 (ja) 2015-04-01
CN101801973B (zh) 2014-03-12
CL2008002351A1 (es) 2009-10-23
HRP20131182T1 (hr) 2014-01-17
TWI429649B (zh) 2014-03-11
JO2935B1 (en) 2016-03-15
TN2010000026A1 (fr) 2011-09-26
JP2010535747A (ja) 2010-11-25
WO2009056692A3 (fr) 2009-06-25
CA2695628C (fr) 2016-11-22
AR068055A1 (es) 2009-11-04
MA31685B1 (fr) 2010-09-01
ME00972B (me) 2012-06-20
US8546393B2 (en) 2013-10-01
NZ583177A (en) 2012-03-30
MX340060B (es) 2016-06-23
PT2178881E (pt) 2013-12-26
CY1114906T1 (el) 2016-12-14
US20150344484A1 (en) 2015-12-03
TW200911816A (en) 2009-03-16
UA101328C2 (uk) 2013-03-25
US20140005189A1 (en) 2014-01-02
CN101801973A (zh) 2010-08-11
DK2178881T3 (da) 2014-01-13
BRPI0815606A2 (pt) 2015-03-03
DOP2010000040A (es) 2010-03-31
SG183077A1 (en) 2012-08-30
PA8792501A1 (es) 2009-04-23
ECSP109944A (es) 2010-03-31
MX2010001593A (es) 2010-10-04
PE20090900A1 (es) 2009-08-06
CA2884102A1 (fr) 2009-05-07
IL203734A (en) 2014-12-31
GT201000023A (es) 2012-04-03
US20100298315A1 (en) 2010-11-25
MY152535A (en) 2014-10-15
US9321777B2 (en) 2016-04-26
KR20100065319A (ko) 2010-06-16
AU2008320791B2 (en) 2013-10-10
AU2008320791A1 (en) 2009-05-07
US9115134B2 (en) 2015-08-25
CR11252A (es) 2010-06-21
WO2009056692A2 (fr) 2009-05-07
CA2695628A1 (fr) 2009-05-07
RS53078B (sr) 2014-06-30
EA201070235A1 (ru) 2010-08-30
UY31277A1 (es) 2009-03-31
ZA201000912B (en) 2011-04-28
SI2178881T1 (sl) 2014-01-31
EP2178881A2 (fr) 2010-04-28
ES2436657T3 (es) 2014-01-03
KR101654376B1 (ko) 2016-09-05
EA023465B1 (ru) 2016-06-30
NI201000022A (es) 2010-03-11
CO6251270A2 (es) 2011-02-21
EP2178881B1 (fr) 2013-10-02

Similar Documents

Publication Publication Date Title
ZA201000912B (en) Novel 6-triazolopyridazinesulfanyl benzothiazole and benzimidazole derivatives,method for production thereof and application as medicaments and pharmaceutical compositions and novel use as met inhibitors
IL205097A0 (en) 6-aryl/heteroalkyloxy benzothiazole and benzimidazole derivatives, method for preparing same, application thereof as drugs, pharmaceutical compositions and novel use in particular as c-met inhibitors
IL206394A (en) Derivatives of 2-Benzylpyridine Filtration as Met Kinase Inhibitors, Process for their Preparation, Medication and Use
ZA200810481B (en) Benzimidazole derivatives, method for the production thereof, their use as FXR agonists and pharmaceutical preparations containing the same
IL196280A0 (en) Use of ampk-activating imidazole derivatives, preparation process therefor and pharmaceutical compositions comprising them
ZA201108373B (en) 1,3-disubstituted imidazolidin-2-one derivatives as inhibitors of cyp 17
IL192845A (en) The history of benzamide and the trower, a process for making them and their pharmaceutical preparations
ZA201001014B (en) (Cyclopropyl-phenyl)-phenyl-oxalamides, method for the production thereof, and use of same as a medicament
IL198301A (en) Aryl amides are stored in thiazole and oxazole, a pharmaceutical preparation containing them and their use in the preparation of drugs
BRPI1014865A2 (pt) "composição e formulação farmacêutica comreendendo derivados de nitrocatecol, e, método para fabricar uma composição ou formulação farmacêutica"
IL210869A (en) Derivatives of imidaziadiazoles, their process, preparation, uses and medications containing them
IL208989A (en) Nip Thiazole Derivatives as 11-Beta-Hydroxy-Steroid-Dehydrogenase-1 Inhibitors, a Process for Manufacturing and Pharmaceuticals and Medications Containing Them
IL211018A (en) Inhibitors, processes for making them, medicinal preparations containing them and their use
SI2242740T1 (sl) SF5-derivati kot PAR1 inhibitorji, njihova priprava in uporaba kot zdravila
SI2107055T1 (sl) Derivati diosmetina, postopek za njihovo pripravo in njihovi farmacevtski sestavki
IL218539A (en) Annotated 4,1-Androsteadian-3-Oxo-9,6-Dihlo-16-Isoxazolidine-17-Noble N-Converted
ZA201100428B (en) Imidazo [1,2-a]pyrimidine derivatives method for the production thereof application thereof as medicaments pharmaceutical compositions and use thereof as met inhibitors
EP2069329A4 (fr) Procédé pour la préparation de dérivés de benzimidazole, et de leurs sels
ZA200902451B (en) Process for the synthesis of derivatives of 3-amino-tetrahydrofuran-3-carboxylic acid and use thereof as medicaments
EP2320738A4 (fr) Dérivés d'aminothiazole substitués, compositions pharmaceutiques et leurs procédés d'utilisation
ZA201004467B (en) Triazolopyridazines as pari inhibitors,production thereof,and use as medicaments
IL189961A0 (en) Novel benzimidazole and benzothiazole derivatives, method for preparing same, use thereof as drugs, pharmaceutical compositions and novel use in particular as c-met inhibitors
IL210975A (en) Annapomapungin History, Pharmaceuticals Containing Them and Their Use in Preparing Medicines to Treat Fungal Infections
SI2147915T1 (sl) Novi cikloalkilirani benzotiadiazinski derivati postopek za njihovo pripravo in farmacevtski sestavki ki jih vsebujejo
HUP0600808A3 (en) New benzamide derivatives as bradykinin antagonists, process for their preparation and pharmaceutical compositions containing them